Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
CAMBRIDGE, Mass., Oct. 25, 2017 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:
| What: | Vericel Corporation Third-Quarter 2017 Earnings Call | ||||||||||||||||||||||
| When: | Tuesday, November 7, 2017 at 8:00am (EST) | ||||||||||||||||||||||
| Where: | http://investors.vcel.com/events.cfm | ||||||||||||||||||||||
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. | ||||||||||||||||||||||
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation third-quarter 2017 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until November 7, 2018. A replay of the call will also be available until 11:00am (EST) on November 11, 2017 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 7097908.
About Vericel Corporation
Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922
